STTK
Shattuck Labs Inc.
$7.72
-$0.02(-0.26%)
63
Overall
60
Value
72
Tech
57
Quality
Market Cap
$512.44M
Volume
421.56K
52W Range
$0.71 - $8.33
Target Price
$12.00
Company Overview
| Mkt Cap | $512.44M | Price | $7.72 |
| Volume | 421.56K | Change | -0.26% |
| P/E Ratio | -6.8 | Open | $7.90 |
| Revenue | $5.7M | Prev Close | $7.74 |
| Net Income | $-75.4M | 52W Range | $0.71 - $8.33 |
| Div Yield | N/A | Target | $12.00 |
| Overall | 63 | Value | 60 |
| Quality | 57 | Technical | 72 |
No chart data available
About Shattuck Labs Inc.
Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate is SL-325, a monoclonal antibody which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
Sector: Industrials
Industry: Pharmaceutical Preparation Manufacturing
Latest News
Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Solventum Corporation (SOLV) and Shattuck Labs (STTK)
Christine Brown•14 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | STTK | $7.72 | -0.3% | 421.56K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |